• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 12, 2025

    2/5/25 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email

    DUBLIN, Feb. 5, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025 to discuss the company's fourth quarter and year-end 2024 financial results. Management will also discuss financial expectations for 2025 and provide an update on the company.

    The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. 

    About Alkermes plc

    Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

    Alkermes Contact:

    Jamie Constantine

    Investor Relations

    +1 781 873 2402

    Alkermes plc Logo (PRNewsfoto/Alkermes plc)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-fourth-quarter-and-year-end-financial-results-on-feb-12-2025-302368996.html

    SOURCE Alkermes plc

    Get the next $ALKS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    11/5/2024$25.00 → $36.00Hold → Buy
    Stifel
    6/17/2024$34.00Buy
    TD Cowen
    3/19/2024$37.00Outperform
    Robert W. Baird
    More analyst ratings

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alkermes Plc upgraded by UBS with a new price target

      UBS upgraded Alkermes Plc from Neutral to Buy and set a new price target of $42.00

      6/17/25 7:46:56 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Alkermes Plc with a new price target

      Needham initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $45.00

      5/28/25 8:55:31 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Alkermes Plc with a new price target

      RBC Capital Mkts initiated coverage of Alkermes Plc with a rating of Sector Perform and set a new price target of $40.00

      3/13/25 7:24:22 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    SEC Filings

    See more
    • Alkermes plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Alkermes plc. (0001520262) (Filer)

      5/21/25 4:15:15 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Alkermes plc

      SCHEDULE 13G - Alkermes plc. (0001520262) (Subject)

      5/13/25 10:23:10 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Alkermes plc

      DEFA14A - Alkermes plc. (0001520262) (Filer)

      5/12/25 5:03:55 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care